Putting the Patient First – How GPs can Improve Outcomes for Patients with Psoriatic Arthritis (PsA) - Certificate of Completion
Psoriatic arthritis (PsA) is a chronic inflammatory disease with a broad range of clinical features and courses. Manifestations can range from the involvement of musculoskeletal structures (including joints, entheses, synovial sheaths of tendons and the axial skeleton) to skin, nail, gut and eye involvement. An increased prevalence of metabolic syndrome, type-2 diabetes mellitus, obesity, hyperlipidaemia, hypertension and cardiovascular disease among patients with PsA has also been well described.
The worldwide prevalence of PsA ranges from 6% to 39% in patients with psoriasis and is equally likely to occur in both males and females. Joint deformities and destruction occur in approximately 40% to 60% of untreated patients. Given the joint destruction, functional impairment, reduced quality of life and psychosocial disability, it is not surprising that the disease burden among individuals with PsA is considered high.
This interactive online learning activity is valued at 1 Hour(s) of continuing education.
Associate Professor Paul Bird,
BMed (Hons), FRACP, PhD, Grad Dip MRI
St George & Sutherland Clinical School
University of New South Wales
VMO, St George Private Hospital, Kogarah, NSW
MBBS, MWell, DipRACOG
South Coast Medical
Blairgowrie, Victoria, Australia
On completion of this program, participants will be better able to:
- Identify features of psoriatic arthritis (PsA) recognise patients who are experiencing active disease and would benefit from timely referral
- Recognise patients whose quality of life is negatively impacted by treatment with disease modifying anti-rheumatic drugs (DMARDs)
- Describe factors that impact treatment targets for patients with PsA, including safety, tolerability and convenience
- Evaluate patient beliefs, attitudes, goals and preferences and thereby address concerns regarding benefits and tolerability of treatment for PsA